Mark Schoeberg sells 10,000 URGN shares
Mark Schoeberg reported a sale of 10,000 ordinary shares of UroGen Pharma Ltd. The sale is listed with a transaction date of 05/08/2026 and an associated value of 300,048.00.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Mark Schoeberg reported a sale of 10,000 ordinary shares of UroGen Pharma Ltd. The sale is listed with a transaction date of 05/08/2026 and an associated value of 300,048.00. The filing also shows 30,000 ordinary shares issued upon vesting of RSUs on 06/08/2023 (no consideration).
Insights
Routine Form 144 sale by an insider; no additional corporate action shown.
The filing lists a reported disposition of 10,000 ordinary shares by Mark Schoeberg with a transaction date of 05/08/2026 and a reported value of 300,048.00. This appears as a standard insider sale filing under resale rules.
Separately, the record shows 30,000 shares issued upon vesting of RSUs on 06/08/2023 described as "no consideration." Timing and broader portfolio context are not provided in the excerpt.
Key Figures
Key Terms
Form 144 regulatory
RSUs financial
No consideration financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does UroGen (URGN) Form 144 report for Mark Schoeberg?
AI-generated analysis. How Rhea-AI works. Not financial advice.